NTRA
Natera, Inc.Healthcare · $47.3B market cap
Verdict
We can't put a fair value on NTRA right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
3 of 5 clear the 10% bar. What are the Big Five?
Follow NTRA
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
4 of the investors we track hold NTRA. In Q2 2026, 1 opened a position and 2 added. Who we track
Insider activity
Since Sep 1, 2026: no open-market purchases and 11 sales worth $22.9M. Why purchases matter
Sales
Rabinowitz Matthew
EXECUTIVE CHAIRMAN · 2026-09-11
Sold
$429K
Rabinowitz Matthew
EXECUTIVE CHAIRMAN · 2026-09-11
Sold
$5.2M
Rabinowitz Matthew
EXECUTIVE CHAIRMAN · 2026-09-11
Sold
$5.9M
Rabinowitz Matthew
EXECUTIVE CHAIRMAN · 2026-09-11
Sold
$3.5M
Rabinowitz Matthew
EXECUTIVE CHAIRMAN · 2026-09-11
Sold
$1.2M
Show all 11 salesShow fewer
Rabinowitz Matthew
EXECUTIVE CHAIRMAN · 2026-09-11
Sold
$260K
Moshkevich Solomon
PRESIDENT, CLINICALDIAGNOSTICS · 2026-09-02
Sold
$5.0M
Chapman Steven Leonard
CEO AND PRESIDENT · 2026-09-01
Sold
$545K
Moshkevich Solomon
PRESIDENT, CLINICALDIAGNOSTICS · 2026-09-01
Sold
$193K
Moshkevich Solomon
PRESIDENT, CLINICALDIAGNOSTICS · 2026-09-01
Sold
$449K
Moshkevich Solomon
PRESIDENT, CLINICALDIAGNOSTICS · 2026-09-01
Sold
$320K
About Natera, Inc.
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders…
Medical - Diagnostics & Research
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works